• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Biomarkers and prognostic factors for mesothelioma.

作者信息

Pass Harvey I

机构信息

Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, New York, NY 10016, USA.

出版信息

Ann Cardiothorac Surg. 2012 Nov;1(4):449-56. doi: 10.3978/j.issn.2225-319X.2012.10.04.

DOI:10.3978/j.issn.2225-319X.2012.10.04
PMID:23977535
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3741796/
Abstract
摘要

相似文献

1
Biomarkers and prognostic factors for mesothelioma.间皮瘤的生物标志物和预后因素。
Ann Cardiothorac Surg. 2012 Nov;1(4):449-56. doi: 10.3978/j.issn.2225-319X.2012.10.04.
2
Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤临床预后指标的血浆生物标志物富集
J Thorac Oncol. 2016 Jun;11(6):900-9. doi: 10.1016/j.jtho.2016.02.006. Epub 2016 Feb 21.
3
Biomarkers and prognostic factors for malignant pleural mesothelioma.恶性胸膜间皮瘤的生物标志物和预后因素
Future Oncol. 2015;11(24 Suppl):29-33. doi: 10.2217/fon.15.317.
4
Prognostic Impact of Inflammation-related Biomarkers on Overall Survival of Patients with Inoperable Malignant Pleural Mesothelioma.炎症相关生物标志物对无法手术的恶性胸膜间皮瘤患者总生存期的预后影响
In Vivo. 2018 Mar-Apr;32(2):445-450. doi: 10.21873/invivo.11260.
5
The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor.可溶性间皮素和巨核细胞促进因子对临床变量的诊断和预后价值的影响。
Chest. 2012 Feb;141(2):477-484. doi: 10.1378/chest.11-0129. Epub 2011 Jul 7.
6
Prognostic factors in malignant pleural mesothelioma.恶性胸膜间皮瘤的预后因素
Hum Pathol. 2015 Jun;46(6):789-804. doi: 10.1016/j.humpath.2015.02.006. Epub 2015 Feb 28.
7
MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma.微小RNA作为恶性间皮瘤预测标志物的诊断和预后价值。
Arch Environ Occup Health. 2020;75(8):471-482. doi: 10.1080/19338244.2020.1747966. Epub 2020 Apr 20.
8
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.几种生物标志物对恶性胸膜间皮瘤患者的预后价值。
Tumour Biol. 2015 Sep;36(10):7375-84. doi: 10.1007/s13277-015-4063-1. Epub 2015 Sep 11.
9
The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.同源盒基因EMX2是恶性胸膜间皮瘤的一个预后和预测标志物。
Lung Cancer. 2014 Sep;85(3):465-71. doi: 10.1016/j.lungcan.2014.06.018. Epub 2014 Jun 30.
10
Prognostic significance of the lymphocyte-to-monocyte ratio in patients with malignant pleural mesothelioma.淋巴细胞与单核细胞比值对恶性胸膜间皮瘤患者的预后意义。
Lung Cancer. 2015 Oct;90(1):111-7. doi: 10.1016/j.lungcan.2015.07.014. Epub 2015 Jul 30.

引用本文的文献

1
The Mesothelioma Systemic Inflammation Score Is Independently Associated with Overall Survival and Predicts Benefit of Multimodality Treatment in Pleural Mesothelioma.间皮瘤全身炎症评分与总生存期独立相关，并可预测胸膜间皮瘤多模式治疗的获益情况。
Cancers (Basel). 2025 Apr 20;17(8):1371. doi: 10.3390/cancers17081371.
2
An Evaluation Into the Robustness of Grading of Pleural Mesothelioma Outside of Specialist Centres.对专科中心以外的胸膜间皮瘤分级稳健性的评估。
APMIS. 2025 Mar;133(3):e70006. doi: 10.1111/apm.70006.
3
PD-L1 expression complements CALGB prognostic scoring system in malignant pleural mesothelioma.程序性死亡配体1（PD-L1）表达补充了CALGB预后评分系统在恶性胸膜间皮瘤中的作用。
Front Oncol. 2023 Dec 4;13:1269029. doi: 10.3389/fonc.2023.1269029. eCollection 2023.
4
Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.多视角下铜死亡促进基因特征的泛癌症分析。
Clin Exp Med. 2023 Dec;23(8):4997-5014. doi: 10.1007/s10238-023-01108-y. Epub 2023 Jun 15.
5
Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression.恶性胸膜间皮瘤：衍生中性粒细胞与淋巴细胞比值及程序性死亡配体1（PD-L1）表达的临床经验及预后价值
Clin Transl Oncol. 2021 Oct;23(10):2030-2035. doi: 10.1007/s12094-021-02605-w. Epub 2021 Apr 10.
6
Elevated Serum Megakaryocyte Potentiating Factor as a Predictor of Poor Survival in Patients with Mesothelioma and Primary Lung Cancer.血清巨核细胞增强因子升高作为间皮瘤和原发性肺癌患者生存不良的预测指标
J Appl Lab Med. 2018 Sep;3(2):166-177. doi: 10.1373/jalm.2017.025015.
7
Genomics and Epigenetics of Malignant Mesothelioma.恶性间皮瘤的基因组学与表观遗传学
High Throughput. 2018 Jul 27;7(3):20. doi: 10.3390/ht7030020.
8
A Novel Panel of Serum Biomarkers for MPM Diagnosis.用于间皮瘤诊断的新型血清生物标志物组合
Dis Markers. 2017;2017:3510984. doi: 10.1155/2017/3510984. Epub 2017 Feb 28.
9
Management of malignant pleural mesothelioma - part 1: epidemiology, diagnosis, and staging : Consensus of the Austrian Mesothelioma Interest Group (AMIG).恶性胸膜间皮瘤的管理 - 第1部分：流行病学、诊断和分期：奥地利间皮瘤兴趣小组（AMIG）共识
Wien Klin Wochenschr. 2016 Sep;128(17-18):611-7. doi: 10.1007/s00508-016-1080-z. Epub 2016 Sep 12.
10
MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.微小RNA-21调节肝癌细胞系HepG2中BTG2的表达。
Mol Med Rep. 2015 Oct;12(4):4917-24. doi: 10.3892/mmr.2015.4051. Epub 2015 Jul 7.

本文引用的文献

1
Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).循环内皮细胞（CEC）作为恶性胸膜间皮瘤（MPM）的诊断和预后标志物。
Ann Surg Oncol. 2012 Dec;19(13):4229-37. doi: 10.1245/s10434-012-2506-0. Epub 2012 Jul 24.
2
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.恶性胸膜间皮瘤预后因素的验证：新南威尔士尘埃疾病委员会寻求赔偿的患者数据的回顾性分析。
Clin Lung Cancer. 2013 Jan;14(1):70-7. doi: 10.1016/j.cllc.2012.03.011. Epub 2012 Jun 1.
3
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM).探索性分析恶性胸膜间皮瘤（MPM）中 PTEN-PI3K 通路及其下游蛋白的激活情况。
Lung Cancer. 2012 Jul;77(1):192-8. doi: 10.1016/j.lungcan.2012.02.022. Epub 2012 Mar 27.
4
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.胸膜外全肺切除术后上皮性恶性胸膜间皮瘤：基于 CT 肿瘤体积的生存分层。
AJR Am J Roentgenol. 2012 Feb;198(2):359-63. doi: 10.2214/AJR.11.7015.
5
Expression of interleukin-4 receptor alpha in human pleural mesothelioma is associated with poor survival and promotion of tumor inflammation.白细胞介素-4 受体α在人胸膜间皮瘤中的表达与不良预后相关，并促进肿瘤炎症。
Clin Cancer Res. 2012 Mar 15;18(6):1568-77. doi: 10.1158/1078-0432.CCR-11-1808. Epub 2012 Jan 18.
6
CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.CD26 过表达与恶性胸膜间皮瘤的生存时间延长和化疗敏感性增强相关。
Clin Cancer Res. 2012 Mar 1;18(5):1447-56. doi: 10.1158/1078-0432.CCR-11-1990. Epub 2012 Jan 18.
7
Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group.浆细胞瘤细胞膜定位的 c-MET 预测恶性间皮瘤患者的生存时间更长：MESOPATH 小组的 157 例系列研究。
J Thorac Oncol. 2012 Mar;7(3):599-606. doi: 10.1097/JTO.0b013e3182417da5.
8
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma.水通道蛋白 1 是胸膜恶性间皮瘤的独立预后因素。
Cancer. 2012 Jun 1;118(11):2952-61. doi: 10.1002/cncr.26497. Epub 2011 Oct 21.
9
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy.钙视网膜蛋白低表达和中性粒细胞与淋巴细胞比值高是行胸膜外全肺切除术的恶性间皮瘤患者的不良预后因素。
J Thorac Oncol. 2011 Nov;6(11):1923-9. doi: 10.1097/JTO.0b013e31822a3740.
10
A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.核分级系统是上皮样弥漫性恶性胸膜间皮瘤生存的有力预测指标。
Mod Pathol. 2012 Feb;25(2):260-71. doi: 10.1038/modpathol.2011.146. Epub 2011 Oct 7.